Altria Group Q1 2024: Sales Reaching $4.72 Billion, Driven by On! and NJOY

Business by 2FIRSTS, edited by Sophia
Apr.26.2024
Altria Group Q1 2024: Sales Reaching $4.72 Billion, Driven by On! and NJOY
Altria Group's Q1 sales surpass expectations at $4.72 billion, driven by rising prices and demand for alternative tobacco products.

The Altria Group, Inc. announced on its official website on April 25th that its first quarter performance of 2024 exceeded expectations, driven by price increases and rising demand for alternative tobacco products. The Q1 sales revenue amounted to $4.72 billion (€4.4 billion) after deducting excise taxes. The shipment volume of nicotine pouches On! increased by 32.1% compared to the previous quarter, reaching 25.2%. The shipment volume of NJOY consumables was approximately 10.9 million units, while NJOY devices totaled around 1 million units. Retail spending in multiple stores and convenience store channels in the US increased by 4.3% in the first quarter, a 0.6% increase from the previous quarter.

 

The report highlights include: 

  • The share of the American nicotine pouch category in the U.S. oral tobacco category has increased to 40.1%, a 13.8% rise compared to the previous year. 
  • The sale of a 10% stake (approximately 35 million shares) in the top beer maker, AB InBev, accounts for about one-fifth of its total holdings. 
  • The adjusted diluted earnings per share guidance range for the full year of 2024 is between $5.05 and $5.17, a 2% to 4.5% increase from $4.95 in 2023. 
  • Marlboro's retail share in the total cigarette category remains at 42.0%, unchanged from the previous year.

 

The CEO of Altria, Billy Gifford, stated during a press conference:

 

We have made significant progress in pursuing our vision, our high-margin traditional tobacco business continues to perform well in a challenging environment. Despite a lack of effective regulatory environment, we see continued early momentum in NJOY and believe our business is on track to meet full-year plans. We have also demonstrated our ongoing commitment to maximizing investment returns and providing strong shareholder returns through the sale of a partial stake in ABI and subsequently expanding our stock buyback program in March.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
RFK Jr. Says Public Should Not Follow His Personal Use of Zyn Nicotine Pouches
RFK Jr. Says Public Should Not Follow His Personal Use of Zyn Nicotine Pouches
According to People, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said in an interview with The Atlantic that although he frequently uses Zyn nicotine pouches, he does not recommend that Americans imitate his personal habits. His use of nicotine products has drawn renewed attention, alongside ongoing scrutiny of his broader health-related positions.
Dec.04
Philip Morris and R.J. Reynolds Face Trial Over Woman’s Lung Cancer Death in Massachusetts
Philip Morris and R.J. Reynolds Face Trial Over Woman’s Lung Cancer Death in Massachusetts
According to Law360, the family of Maria Petruzziello has taken Philip Morris and R.J. Reynolds to trial in Massachusetts, alleging the companies are responsible for her 2019 lung cancer death after decades of smoking. Plaintiffs argue her experience mirrors many smokers, while the defense points to her years-long cessation and personal choice.
Dec.03 by 2FIRSTS.ai
NZ Issues National High Alert on Etomidate-Laced Vapes After Hospitalisations
NZ Issues National High Alert on Etomidate-Laced Vapes After Hospitalisations
New Zealand’s High Alert drug harm monitoring system has issued a public High Alert warning after multiple hospitalisations linked to illicit vape pods containing the anaesthetic etomidate. Known on the street as space oil, k-pods, or eto, these vapes were first detected in January 2025. Customs has since seized additional samples, and clinics nationwide report rising cases of poisoning and hypoglycaemia.
Nov.04 by 2FIRSTS.ai
BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill
BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill
The Guardian reports that British American Tobacco urged Zambian ministers to drop or delay ad and sponsorship bans and to soften a draft tobacco bill by shrinking health warnings, easing flavour restrictions and lowering penalties. Critics said the stance is hypocritical given similar rules apply in the UK.
Nov.13
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
SKE has launched the V-BOT disposable e-cigarette. The company’s website highlights that the device is “Made in the USA,” with blending and filling also completed domestically. The V-BOT features dual power modes (Eco/Boost), an 800 mAh rechargeable battery, and is advertised as delivering up to 40,000 puffs.
Nov.07 by 2FIRSTS.ai